Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
Proc Natl Acad Sci U S A. 2012;109(43):17561-6 - PMID: 23045683 - PMCID: PMC3491458 - DOI: 10.1073/pnas.1215397109
Duda DG, Willett CG
Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?
Oncology (Williston Park). 2012;26(8):741-3 - PMID: 22957407 - PMCID: PMC3682651
Kozin SV, Duda DG, Munn LL, Jain RK
Neovascularization After Irradiation: What is the Source of Newly Formed Vessels in Recurring Tumors?
J Natl Cancer Inst. 2012;104(12):899-905 - PMID: 22572994 - PMCID: PMC3379722 - DOI: 10.1093/jnci/djs239
Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
PLoS One. 2012;7(6):e38231 - PMID: 22701615 - PMCID: PMC3373492 - DOI: 10.1371/journal.pone.0038231
Dima SO, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I
An Exploratory Study of Inflammatory Cytokines as Prognostic Biomarkers in Patients With Ductal Pancreatic Adenocarcinoma.
Pancreas. 2012;41(7):1001-7 - PMID: 22722257 - DOI: 10.1097/MPA.0b013e3182546e13
Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.
Oncologist. 2012;17(2):212-9 - PMID: 22302227 - PMCID: PMC3286170 - DOI: 10.1634/theoncologist.2011-0321
Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
PLoS One. 2012;7(2):e26331 - PMID: 22347360 - PMCID: PMC3274514 - DOI: 10.1371/journal.pone.0026331
Duyverman AM, Kohno M, Roberge S, Fukumura D, Duda DG, Jain RK
An isolated tumor perfusion model in mice.
Nat Protoc. 2012;7(4):749-55 - PMID: 22441293 - PMCID: PMC3375334 - DOI: 10.1038/nprot.2012.030
Duyverman AM, Steller EJ, Fukumura D, Jain RK, Duda DG
Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice.
Nat Protoc. 2012;7(4):756-62 - PMID: 22441294 - PMCID: PMC3380105 - DOI: 10.1038/nprot.2012.031
Duyverman AM, Kohno M, Duda DG, Jain RK, Fukumura D
A transient parabiosis skin transplantation model in mice.
Nat Protoc. 2012;7(4):763-70 - PMID: 22441295 - PMCID: PMC3375333 - DOI: 10.1038/nprot.2012.032
Dawson MR, Chae SS, Jain RK, Duda DG
Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression.
Am J Cancer Res. 2011;1(2):144-54 - PMID: 21822499 - PMCID: PMC3150110
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK
Normalization of the vasculature for treatment of cancer and other diseases.
Physiol Rev. 2011;91(3):1071-121 - PMID: 21742796 - PMCID: PMC3258432 - DOI: 10.1152/physrev.00038.2010
Kozin SV, Duda DG, Munn LL, Jain RK
Is vasculogenesis crucial for the regrowth of irradiated tumours?
Nat Rev Cancer. 2011;11(7):532 - PMID: 21701514 - PMCID: PMC4790119 - DOI: 10.1038/nrc2007-c1
Zhu AX, Duda DG, Sahani DV, Jain RK
HCC and angiogenesis: possible targets and future directions.
Nat Rev Clin Oncol. 2011;8(5):292-301 - PMID: 21386818 - PMCID: PMC3266719 - DOI: 10.1038/nrclinonc.2011.30
Duda DG
Targeting Tumor Angiogenesis: Biomarkers of Angiogenesis and Antiangiogenic Therapy in Cancer
Angiogenesis Foundation CME e-publication. 2011;:ePub
di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK
Glioblastoma recurrence after cediranib therapy in patients: lack of rebound revascularization as mode of escape.
Cancer Res. 2011;71(1):19-28 - PMID: 21199795 - PMCID: PMC3074948 - DOI: 10.1158/0008-5472.CAN-10-2602
Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
J Neurooncol. 2011;103(2):325-32 - PMID: 20821342 - PMCID: PMC4090923 - DOI: 10.1007/s11060-010-0390-7
Hiratsuka S, Goel S, Kamoun WS, Maru Y, Fukumura D, Duda DG, Jain RK
Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation.
Proc Natl Acad Sci U S A. 2011;108(9):3725-30 - PMID: 21321210 - PMCID: PMC3048115 - DOI: 10.1073/pnas.1100446108
Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
Clin Cancer Res. 2011;17(8):2074-80 - PMID: 21349998 - PMCID: PMC3079023 - DOI: 10.1158/1078-0432.CCR-10-2636
Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
Clin Ovarian Cancer Other Gynecol Malig. 2011;4(1):26-33 - PMID: 21833345 - PMCID: PMC3151740 - DOI: 10.1016/j.cloc.2011.04.003
Fukumura D, Duda DG, Munn LL, Jain RK
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models.
Microcirculation. 2010;17(3):206-25 - PMID: 20374484 - PMCID: PMC2859831 - DOI: 10.1111/j.1549-8719.2010.00029.x
Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK
Malignant cells facilitate lung metastasis by bringing their own soil.
Proc Natl Acad Sci U S A. 2010;107(50):21677-82 - PMID: 21098274 - PMCID: PMC3003109 - DOI: 10.1073/pnas.1016234107
Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(8):845-51 - PMID: 20667969 - PMCID: PMC3078712 - DOI: 10.1634/theoncologist.2010-0030
Duda DG, Jain RK
Premetastatic lung niche: is vascular endothelial growth factor receptor 1 activation required?
Cancer Res. 2010;70(14):5670-3 - PMID: 20587530 - PMCID: PMC2919170 - DOI: 10.1158/0008-5472.CAN-10-0119
Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(6):577-83 - PMID: 20484123 - PMCID: PMC3061828 - DOI: 10.1634/theoncologist.2010-0029
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
J Clin Oncol. 2010;28(17):2817-23 - PMID: 20458050 - PMCID: PMC2903316 - DOI: 10.1200/JCO.2009.26.3988
Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG
Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.
Cancer Res. 2010;70(14):5679-85 - PMID: 20631066 - PMCID: PMC2918387 - DOI: 10.1158/0008-5472.CAN-09-4446
Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT
The potential utility of anti-VEGF agents to normalize tumor vasculature and alleviate edema in brain and spinal cord tumor patients.
Nat Clin Pract Oncol. 2009;6:229-36
Perentes JY, Duda DG, Jain RK
Visualizing anti-tumor immune responses in vivo.
Dis Model Mech. 2009;2(3-4):107-10 - PMID: 19259379 - PMCID: PMC2650205 - DOI: 10.1242/dmm.001842
Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
J Clin Oncol. 2009;27(18):3020-6 - PMID: 19470921 - PMCID: PMC2702234 - DOI: 10.1200/JCO.2008.21.1771
Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG
Biomarkers of response and resistance to antiangiogenic therapy.
Nat Rev Clin Oncol. 2009;6(6):327-38 - PMID: 19483739 - PMCID: PMC3057433 - DOI: 10.1038/nrclinonc.2009.63
Zhu AX, Duda DG, Sahani DV, Jain RK
Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Cancer J. 2009;15(4):263-8 - PMID: 19672141 - PMCID: PMC4792519 - DOI: 10.1097/PPO.0b013e3181af5e35
Au P, Tam J, Duda DG, Lin PC, Munn LL, Fukumura D, Jain RK
Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo.
Am J Pathol. 2009;175(1):294-302 - PMID: 19477947 - PMCID: PMC2708815 - DOI: 10.2353/ajpath.2009.080887
Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
J Clin Oncol. 2009;27(18):3027-35 - PMID: 19470923 - PMCID: PMC2702235 - DOI: 10.1200/JCO.2008.20.9908
Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
Nat Rev Clin Oncol. 2009;6(4):229-36 - PMID: 19333229 - PMCID: PMC4793889 - DOI: 10.1038/nrclinonc.2009.14
Dawson MR, Duda DG, Fukumura D, Jain RK
VEGFR1-activity-independent metastasis formation.
Nature. 2009;461(7262):E4; discussion E5 - PMID: 19759568 - PMCID: PMC3065241 - DOI: 10.1038/nature08254
Dawson MR, Duda DG, Chae SS, Fukumura D, Jain RK
VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.
PLoS One. 2009;4(9):e6525 - PMID: 19763275 - PMCID: PMC2744279 - DOI: 10.1371/journal.pone.0006525
Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
Cancer Res. 2009;69(20):7905-10 - PMID: 19826039 - PMCID: PMC2859041 - DOI: 10.1158/0008-5472.CAN-09-2099
Jain RK, Duda DG, Sorensen AG
Emerging paradigms and potential biomarkers of response and resistance in anatiangiogenic therapy of cancer
ASCO 2009 Educational Book. 2009;:716-21
Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials.
Int J Radiat Oncol Biol Phys. 2009;74(5):1580-91 - PMID: 19540073 - DOI: 10.1016/j.ijrobp.2009.03.047
Tam J, Duda DG, Perentes JY, Quadri RS, Fukumura D, Jain RK
Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells.
PLoS One. 2009;4(3):e4974 - PMID: 19333381 - PMCID: PMC2659427 - DOI: 10.1371/journal.pone.0004974
Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
J Clin Oncol. 2009;27(15):2542-52 - PMID: 19332720 - PMCID: PMC2739611 - DOI: 10.1200/JCO.2008.19.9356
Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Cancer Res. 2009;69(13):5296-300 - PMID: 19549889 - PMCID: PMC2824172 - DOI: 10.1158/0008-5472.CAN-09-0814
Jones R, Capen DE, Jacobson M, Cohen KS, Scadden DT, Duda DG
VEGFR2+PDGFRbeta+ circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI).
J Cell Mol Med. 2009;13(9B):3720-9 - PMID: 19426150 - PMCID: PMC2832073 - DOI: 10.1111/j.1582-4934.2009.00785.x
Willett CG, Duda DG, Xu L, diTomaso E, Boucher Y, Czito B, Ancukiewicz M, Clark J, Carroll M, Lauwers G, Jain RK
Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC).
J Clin Oncol. 2008;26(15_suppl):4096 - PMID: 27949464
Jain RK, Duda DG, Batchelor TT, Sorensen AG, Willett CG
Normalization of tumor vasculature and microenvironment.
In: Angiogenesis: An Integrative Approach from Science to Medicine (Editors: W. D. Figg and J. Folkman), Springer. 2008;:173-282
Jain RK, Duda DG
Vascular and interstitial biology of tumors
In: Clinical Oncology. 4th Edition, (Editors: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG), Elsevier, Philadelphia. 2008;:105-24
Jones RC, Capen DE, Cohen KS, Munn LL, Jain RK, Duda DG
A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents.
Nat Protoc. 2008;3(3):388-97 - PMID: 18323810 - PMCID: PMC2676340 - DOI: 10.1038/nprot.2007.537
Jones RC, Capen D, Petersen B, Jain RK, Duda DG
A protocol for a lung neovascularization model in rodents.
Nat Protoc. 2008;3(3):378-87 - PMID: 18323809 - PMCID: PMC2676330 - DOI: 10.1038/nprot.2007.536
Huang P, Duda DG, Jain RK, Fukumura D
Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice.
Comp Med. 2008;58(3):253-63 - PMID: 18589867 - PMCID: PMC2693079
Jain RK, Batchelor TT, Duda DG, Willett CG
Normalization of tumor vasculature and microenvironment.
In: Antiangiogenic Agents in Cancer Therapy. (Editors: Beverly Teicher and Lee Ellis), Humana Press. 2007;:261-76
Jain RK, Duda DG
Normalization of tumor vasculature and microenvironment by antiangiogenic therapy.
In: Angiogenesis: Mechanisms and Cancer Therapy (Editors: Dieter Marm and Norbert E. Fusenig), Springer-Verlag, Berlin. 2007;:577-92
Jain RK, Duda DG
Angiogenesis in Solid Tumors
In: Antiangiogenic Cancer Therapy (Editors: James L. Abbruzzese, Darren W. Davis and Roy S. Herbst), CRC Press, Boca Raton. 2007;:43-90
Willett CG, Duda DG, Jain RK
Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer.
Current Colorectal Cancer Reports. 2007;3:94-98
Duda DG, Cohen KS, Au P, Scadden DT, Willett CG, Jain RK
Detection of circulating endothelial cells: CD146- based magnetic separation enrichment or flow cytometric assay?
J Clin Oncol. 2007;25:e3-e5
Duda DG
Endothelial cell-based therapy for hematopoiesis
Blood. 2007;109(6):2272-3
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer Cell. 2007;11(1):83-95 - PMID: 17222792 - PMCID: PMC2748664 - DOI: 10.1016/j.ccr.2006.11.021
Duda DG, Cohen KS, Scadden DT, Jain RK
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.
Nat Protoc. 2007;2(4):805-10 - PMID: 17446880 - PMCID: PMC2686125 - DOI: 10.1038/nprot.2007.111
Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT
Angiogenesis in brain tumours.
Nat Rev Neurosci. 2007;8(8):610-22 - PMID: 17643088 - DOI: 10.1038/nrn2175
Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT
Antiangiogenic agents for the treatment of glioblastoma.
Expert Opin Investig Drugs. 2007;16(12):1895-908 - PMID: 18041999 - DOI: 10.1517/13543784.16.12.1895
Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK
Targeted therapy in rectal cancer.
Oncology (Williston Park). 2007;21(9):1055-65; discussion 1065, 1070, 1075 passim - PMID: 17910311 - PMCID: PMC2686129
Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwig KA, Jain RK
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
Nat Clin Pract Oncol. 2007;4(5):316-21 - PMID: 17464339 - PMCID: PMC2686127 - DOI: 10.1038/ncponc0813
Duda DG
American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer.
IDrugs. 2007;10(6):366-9 - PMID: 17641996
Duda DG, Batchelor TT, Willett CG, Jain RK
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
Trends Mol Med. 2007;13(6):223-30 - PMID: 17462954 - PMCID: PMC2686126 - DOI: 10.1016/j.molmed.2007.04.001
Duda DG, Jain RK, Willett CG
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.
J Clin Oncol. 2007;25(26):4033-42 - PMID: 17827451 - PMCID: PMC2686120 - DOI: 10.1200/JCO.2007.11.3985
Jain RK, Duda DG, Clark JW, Loeffler JS
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
Nat Clin Pract Oncol. 2006;3(1):24-40 - PMID: 16407877 - DOI: 10.1038/ncponc0403
Duda DG
Antiangiogenesis and drug delivery to tumors: bench to bedside and back.
Cancer Res. 2006;66(8):3967-70 - PMID: 16618712 - DOI: 10.1158/0008-5472.CAN-05-4536
Hagendoorn J, Padera TP, Yock TI, Nielsen GP, di Tomaso E, Duda DG, Delaney TF, Gaissert HA, Pearce J, Rosenberg AE, Jain RK, Ebb DH
Platelet-derived growth factor receptor-beta in Gorham's disease.
Nat Clin Pract Oncol. 2006;3(12):693-7 - PMID: 17139320 - PMCID: PMC2693369 - DOI: 10.1038/ncponc0660
Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage.
Proc Natl Acad Sci U S A. 2006;103(4):855-60 - PMID: 16418262 - PMCID: PMC1348013 - DOI: 10.1073/pnas.0510412103
Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain RK
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.
J Clin Oncol. 2006;24(9):1449-53 - PMID: 16549839 - PMCID: PMC2718681 - DOI: 10.1200/JCO.2005.04.2861
Willett CG, Kozin SV, Duda DG, di Tomaso E, Kozak KR, Boucher Y, Jain RK
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.
Semin Oncol. 2006;33(5 Suppl 10):S35-40 - PMID: 17145523 - PMCID: PMC2686124 - DOI: 10.1053/j.seminoncol.2006.08.007
Jain RK, Au P, Tam J, Duda DG, Fukumura D
Engineering vascularized tissue.
Nat Biotechnol. 2005;23(7):821-3 - PMID: 16003365 - DOI: 10.1038/nbt0705-821
Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
J Clin Oncol. 2005;23(31):8136-9 - PMID: 16258121 - DOI: 10.1200/JCO.2005.02.5635
Duda DG, Jain RK
Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow.
J Clin Invest. 2005;115(3):596-8 - PMID: 15765145 - PMCID: PMC1052004 - DOI: 10.1172/JCI24511
Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo.
Nat Med. 2005;11(6):678-82 - PMID: 15880117 - PMCID: PMC2686110 - DOI: 10.1038/nm1247
Willett CG, Duda DG, Fischman A, Jain RK
Correspondence: PET concerns in bevacizumab treatment
Nature Medicine. 2004;10:561
Duda DG, Fukumura D, Jain RK
Role of eNOS in neovascularization: NO for endothelial progenitor cells.
Trends Mol Med. 2004;10(4):143-5 - PMID: 15162796 - DOI: 10.1016/j.molmed.2004.02.001
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Nat Med. 2004;10(2):145-7 - PMID: 14745444 - PMCID: PMC2693485 - DOI: 10.1038/nm988
Duda DG, Fukumura D, Munn LL, Booth MF, Brown EB, Huang P, Seed B, Jain RK
Differential transplantability of tumor-associated stromal cells.
Cancer Res. 2004;64(17):5920-4 - PMID: 15342367 - DOI: 10.1158/0008-5472.CAN-04-1268
Sunamura M, Lefter LP, Duda DG, Morita R, Inoue H, Yokoyama T, Yatsuoka T, Abe T, Egawa S, Furukawa T, Fukushige S, Oshimura M, Horii A, Matsuno S
The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma.
Pancreas. 2004;28(3):311-6 - PMID: 15084978 - DOI: 10.1097/00006676-200404000-00019
Jain RK, Duda DG
Role of bone marrow-derived cells in tumor angiogenesis and treatment.
Cancer Cell. 2003;3(6):515-6 - PMID: 12842078 - DOI: 10.1016/s1535-6108(03)00138-7
Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, Matsuno S, Shibahara S, Abraham NG
Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer.
Angiogenesis. 2003;6(1):15-24 - PMID: 14517400 - DOI: 10.1023/a:1025803600840
Duda DG, Sunamura M, Lefter LP, Furukawa T, Yokoyama T, Yatsuoka T, Abe T, Inoue H, Motoi F, Egawa S, Matsuno S, Horii A
Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.
Oncogene. 2003;22(44):6857-64 - PMID: 14534532 - DOI: 10.1038/sj.onc.1206751
Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K, Garkavtsev I, Jain RK
Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis.
Circ Res. 2003;93(9):e88-97 - PMID: 14525808 - PMCID: PMC2755542 - DOI: 10.1161/01.RES.0000099243.20096.FA
Sunamura M, Yatsuoka T, Motoi F, Duda DG, Kimura M, Abe T, Yokoyama T, Inoue H, Oonuma M, Takeda K, Matsuno S
Gene therapy for pancreatic cancer based on genetic characterization of the disease.
J Hepatobiliary Pancreat Surg. 2002;9(1):32-8 - PMID: 12021895 - DOI: 10.1007/s005340200002
Lefter LP, Furukawa T, Sunamura M, Duda DG, Takeda K, Kotobuki N, Oshimura M, Matsuno S, Horii A
Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines.
Genes Chromosomes Cancer. 2002;34(2):234-42 - PMID: 11979557 - DOI: 10.1002/gcc.10060
Hoshida T, Sunamura M, Duda DG, Egawa S, Miyazaki S, Shineha R, Hamada H, Ohtani H, Satomi S, Matsuno S
Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor.
Pancreas. 2002;25(2):111-21 - PMID: 12142732 - DOI: 10.1097/00006676-200208000-00001
Ding L, Sunamura M, Kodama T, Yamauchi J, Duda DG, Shimamura H, Shibuya K, Takeda K, Matsuno S
In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells
Br J Cancer. 2001;85:431-8 - PMID: 11487277 - PMCID: PMC2364062 - DOI: 10.1054/bjoc.2001.1911
Sunamura M, Sun L, Lozonschi L, Duda DG, Kodama T, Matsumoto G, Shimamura H, Takeda K, Kobari M, Hamada H, Matsuno S
The antiangiogenesis effect of interleukin 12 during early growth of human pancreatic cancer in SCID mice.
Pancreas. 2000;20(3):227-33 - PMID: 10766447 - DOI: 10.1097/00006676-200004000-00002
Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K, Matsuno S
Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.
Cancer Res. 2000;60(4):1111-6 - PMID: 10706132
Motoi F, Sunamura M, Ding L, Duda DG, Yoshida Y, Zhang W, Matsuno S, Hamada H
Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus.
Hum Gene Ther. 2000;11(2):223-35 - PMID: 10680837 - DOI: 10.1089/10430340050015978
91